Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 321.2% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 132,099 shares of the company’s stock after purchasing an additional 100,740 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Mineralys Therapeutics were worth $3,579,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of MLYS. State Street Corp grew its position in shares of Mineralys Therapeutics by 144.4% during the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock worth $115,584,000 after acquiring an additional 1,881,976 shares during the last quarter. Farallon Capital Management LLC purchased a new position in Mineralys Therapeutics in the 3rd quarter valued at about $63,442,000. Price T Rowe Associates Inc. MD boosted its position in shares of Mineralys Therapeutics by 6,097.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company’s stock worth $48,089,000 after acquiring an additional 1,303,737 shares during the last quarter. Holocene Advisors LP purchased a new stake in shares of Mineralys Therapeutics during the 3rd quarter worth about $45,708,000. Finally, Janus Henderson Group PLC boosted its position in Mineralys Therapeutics by 6,012.8% during the 4th quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company’s stock worth $44,005,000 after purchasing an additional 1,193,417 shares during the period. 84.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on MLYS. Bank of America upped their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Finally, Wall Street Zen lowered Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Mineralys Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $49.33.

Mineralys Therapeutics Trading Up 4.0%

Shares of MLYS traded up $1.17 during mid-day trading on Tuesday, hitting $30.29. 435,596 shares of the company traded hands, compared to its average volume of 1,403,943. The stock has a market capitalization of $2.50 billion, a price-to-earnings ratio of -14.81 and a beta of 0.66. The business has a 50-day moving average of $27.09 and a 200 day moving average of $29.06. Mineralys Therapeutics, Inc. has a one year low of $12.59 and a one year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.04. As a group, analysts anticipate that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 75,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the completion of the transaction, the chief executive officer owned 614,321 shares of the company’s stock, valued at approximately $16,058,350.94. This trade represents a 10.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Eric Warren sold 104,124 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $25.90, for a total value of $2,696,811.60. Following the completion of the transaction, the insider owned 38,400 shares of the company’s stock, valued at approximately $994,560. This represents a 73.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 266,831 shares of company stock valued at $6,995,829. Company insiders own 18.94% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.